ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

enzalutamide

Also written as “Enzalutamide”, “MDV3100” and “HC-1119”.

Its studies are mostly in Prostatic Neoplasms · Neoplasms · Breast Neoplasms · Prostatic Neoplasms, Castration-Resistant · Neoplasm Metastasis, led by 6 companies.

Drug pageEnzalutamide: every studyMany companies study it; this page follows only the 54 they lead. All 176 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Oct 31, 201354 company-led studies, 7 open or runningNext primary completion: Apr 30, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Astellas Pharmaits history only313 open or runningphase 4since Oct 31, 2013Jan 18, 2011Apr 30, 2027phase 1 · NCT07783282
Pfizer162 open or runningphase 4since Nov 18, 2013Jul 31, 2007none ahead
Hinova Pharmaceuticalsits history only41 open or runningphase 3since Feb 17, 2019Dec 11, 2018none ahead
Alessa Therapeuticsits history only11 open or runningphase 1since Dec 14, 2023Dec 14, 2023Dec 30, 2028phase 1 · NCT06257693
Applied Biologyits history only10 open or runningphase 3since Jul 28, 2021Jul 28, 2021none ahead
Hinova Pharmaceuticals USAits history only10 open or runningphase 3since Feb 20, 2019Feb 20, 2019none ahead

Also a collaborator on its studies: Exelixis, Novartis, Clovis Oncology, Johnson & Johnson, Medivation LLC, a wholly owned subsidiary of Pfizer and Gilead Sciences.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 2 studies since Jul 31, 2007.

  1. Mar 19, 2010Phase 2 study in Metastatic Progressive Castration-resistant Prostate CancerNCT01091103 · 60 enrolled · United States
  2. Sep 29, 2010Phase 3 study in Prostatic NeoplasmsNCT01212991 · 1,717 enrolled · United States, Australia, Austria and more
  3. Feb 8, 2012Phase 1 study in Prostatic NeoplasmsNCT01565928 · 23 enrolled · United States
  4. Feb 27, 2012Phase 2 study in Prostatic NeoplasmsNCT01547299 · 52 enrolled · United States, Canada
  5. May 9, 2012Phase 1 study in Breast NeoplasmsNCT01597193 · 101 enrolled · United States
  6. Aug 10, 2012Phase 2 study in Prostatic NeoplasmsNCT01664923 · 396 enrolled · United States
  7. Jun 26, 2013Phase 2 study in Breast NeoplasmsNCT01889238 · 118 enrolled · United States, Belgium, Canada and more
  8. Nov 18, 2013Phase 4 study in Prostatic NeoplasmsNCT01995513 · 509 enrolled · United States, Australia, Belgium and more
  9. Dec 3, 2013Phase 2 study in Breast NeoplasmsNCT02007512 · 247 enrolled · United States, Belgium, Canada and more
  10. Dec 3, 2013Phase 3 study in Prostatic NeoplasmsNCT02003924 · 1,401 enrolled · United States, Argentina, Australia and more
  11. Dec 14, 2014Phase 3 study in Prostatic NeoplasmsNCT02319837 · 1,068 enrolled · United States, Australia, Austria and more
  12. Mar 4, 2015Phase 2 study in Prostatic NeoplasmsNCT02384382 · 23 enrolled · United States
  13. Sep 7, 2016Phase 3 study in Breast NeoplasmsNCT02929576 · United States
  14. Mar 25, 2021Phase 3 study in Prostatic NeoplasmsNCT04821622 · 599 enrolled · United States, Argentina, Australia and more

TargetBeta

AR →read by rule
“A deuterated form of enzalutamide, an orally bioavailable, organic, non-steroidal small molecule targeting the androgen receptor (AR) ”NCIt, by rule
“Androgen Receptor antagonist”ChEMBL 37, by rule

Other programs on AR

ProgramCompanyFurthest phaseStudies
apalutamideruleJohnson & Johnsonphase 431
darolutamideruleBayerphase 426
Clascoteronerulecassiopea-spaphase 419
ostarinerulegtxphase 315
rezvilutamideruleJiangsu HengRui Medicinephase 313
dezandrodegruleBristol-Myers Squibbphase 35
Cyproterone AcetateruleEurofarma Laboratoriosphase 34
Androgen Receptor-targeting Regulated Induced Proximity Targeting Chimera HLD-0915Johnson & Johnsonphase 33
HRS-5041Jiangsu HengRui Medicinephase 26
luxdegalutamideNovartisphase 23
luxdegalutamideNovartisphase 22
Androgen Receptor Degrader AZD9750ruleAstraZenecaphase 21

Studies

All 16 Pfizer leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04821622Prostatic Neoplasms · United States, Argentina, Australia and more3Active, not recruitingFeb 18, 2026599
NCT02929576Breast Neoplasms · United States3WithdrawnApr 20190
NCT02384382Prostatic Neoplasms · United States2CompletedMay 3, 201923
NCT02319837Prostatic Neoplasms · United States, Australia, Austria and more3Active, not recruitingJan 31, 20231,068
NCT02007512Breast Neoplasms · United States, Belgium, Canada and more2CompletedSep 23, 2016247
NCT02003924Prostatic Neoplasms · United States, Argentina, Australia and more3CompletedJun 28, 20171,401
NCT01995513Prostatic Neoplasms · United States, Australia, Belgium and more4CompletedNov 15, 2016509
NCT01889238Breast Neoplasms · United States, Belgium, Canada and more2CompletedMar 1, 2015118
NCT01664923Prostatic Neoplasms · United States2CompletedFeb 2015396
NCT01597193Breast Neoplasms · United States1CompletedDec 15, 2015101
NCT01547299Prostatic Neoplasms · United States, Canada2CompletedNov 30, 201352
NCT01565928Prostatic Neoplasms · United States1CompletedJul 1, 201323
NCT01212991Prostatic Neoplasms · United States, Australia, Austria and more3CompletedSep 30, 20131,717
NCT01091103Metastatic Progressive Castration-resistant Prostate Cancer · United States2CompletedFeb 29, 201260
NCT00974311Prostatic Neoplasms · United States, Argentina, Australia and more3CompletedSep 15, 20111,199
NCT00510718Prostatic Neoplasms · United States1CompletedDec 8, 2008140

How it is read

Names in the registry

  • “Enzalutamide”, 40 entries
  • “enzalutamide”, 13 entries
  • “MDV3100”, 8 entries
  • “HC-1119”, 4 entries
  • “HC1119”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.